Development and external validation of a clinical prediction model for survival in patients with IDH wild-type glioblastoma

Author:

Mijderwijk Hendrik-Jan1,Nieboer Daan2,Incekara Fatih31,Berger Kerstin1,Steyerberg Ewout W.24,van den Bent Martin J.5,Reifenberger Guido6,Hänggi Daniel1,Smits Marion3,Senft Christian78,Rapp Marion1,Sabel Michael1,Voss Martin9,Forster Marie-Therese7,Kamp Marcel A.18

Affiliation:

1. Departments of Neurosurgery and

2. Departments of Public Health and

3. Radiology & Nuclear Medicine, Erasmus MC, University Medical Center, Rotterdam;

4. Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, The Netherlands;

5. Neurology, Brain Tumor Centre, Erasmus MC Cancer Institute, University Medical Center, Rotterdam;

6. Neuropathology, Heinrich Heine University, Medical Faculty, Düsseldorf, Germany;

7. Department of Neurosurgery, and

8. Department of Neurosurgery, Friedrich Schiller University, Medical Faculty, Jena, Germany

9. Dr. Senckenberg Institute of Neurooncology, Goethe University, Medical Faculty, Frankfurt; and

Abstract

OBJECTIVE Prognostication of glioblastoma survival has become more refined due to the molecular reclassification of these tumors into isocitrate dehydrogenase (IDH) wild-type and IDH mutant. Since this molecular stratification, however, robust clinical prediction models relevant to the entire IDH wild-type glioblastoma patient population are lacking. This study aimed to provide an updated model that predicts individual survival prognosis in patients with IDH wild-type glioblastoma. METHODS Databases from Germany and the Netherlands provided data on 1036 newly diagnosed glioblastoma patients treated between 2012 and 2018. A clinical prediction model for all-cause mortality was developed with Cox proportional hazards regression. This model included recent glioblastoma-associated molecular markers in addition to well-known classic prognostic variables, which were updated and refined with additional categories. Model performance was evaluated according to calibration (using calibration plots and calibration slope) and discrimination (using a C-statistic) in a cross-validation procedure by country to assess external validity. RESULTS The German and Dutch patient cohorts consisted of 710 and 326 patients, respectively, of whom 511 (72%) and 308 (95%) had died. Three models were developed, each with increasing complexity. The final model considering age, sex, preoperative Karnofsky Performance Status, extent of resection, O6-methylguanine DNA methyltransferase (MGMT) promoter methylation status, and adjuvant therapeutic regimen showed an optimism-corrected C-statistic of 0.73 (95% confidence interval 0.71–0.75). Cross-validation between the national cohorts yielded comparable results. CONCLUSIONS This prediction model reliably predicts individual survival prognosis in patients with newly diagnosed IDH wild-type glioblastoma, although additional validation, especially for long-term survival, may be desired. The nomogram and web application of this model may support shared decision-making if used properly.

Publisher

Journal of Neurosurgery Publishing Group (JNSPG)

Subject

Genetics,Animal Science and Zoology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3